Device Trial Radar · NCT04292405
Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator
Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
60
Actual
Start
Jan 23, 2020
Primary completion
Sep 30, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Zoll Medical CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 3, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Evaluate data accuracy of cardiac acoustic biomarkers (CABs) recorded by the Wearable Cardioverter Defibrillator (WCD) as compared to the AUDICOR AM acoustic cardiography recorder.
Conditions
- Heart Failure
Interventions
Wearable Cardioverter DefibrillatorDevice
Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CABs comparisonTime frame: 2 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MAYO Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.